Shubham Pant

机构：The University of Texas MD Anderson Cancer Center · ORCID：0000-0001-9055-8494

发表论文 32 篇 · 总被引 81 次 · h-index 6

代表论文

• KRAS G12D -Specific Targeting with Engineered Exosomes Reprograms the Immune Microenvironment to Enable Efficacy of Immune Checkpoint Therapy in PDAC Patients (2025 · medRxiv · 被引 18)
• Trial in progress: RASolute 302—A phase 3, multicenter, global, open-label, randomized study of daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor, versus standard of care chemotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). (2025 · Journal of Clinical Oncology · 被引 15)
• Zanidatamab in HER2-Positive Metastatic Biliary Tract Cancer (2025 · JAMA Oncology · 被引 13)
• Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Primary and final analysis from the phase 3 RASolute 302 study. (2026 · Journal of Clinical Oncology · 被引 11)
• Population-Specific Immunogenomic Alterations in Gallbladder Cancer and Prognostic Significance (2025 · Modern Pathology · 被引 6)
• Impact of HER2-positivity on prognosis and targeted therapeutic outcomes in advanced biliary tract cancer. (2025 · Journal of Clinical Oncology · 被引 4)